ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VRDN / financials
VCRE (49) MBX (40) NRIX (46) BHC (68) ⌘ Pro Terminal →

Viridian Therapeutics Inc. (VRDN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$25.30 +2.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.37

Viridian Therapeutics Inc. (VRDN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.79B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VRDN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $25.30 (+2.55% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VRDN ranks #359 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VRDN compare to VCRE and MBX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VRDN?
▼

Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $1.02B in revenue (+21.5% YoY), -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $25.37 (+0.27%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (7)Whales (15)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$36 Bull$24 Base$19 Bear
📬 FREE VRDN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRDN)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY VRDN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±9.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$18.22+23.1% Next Q
Q2 (-2Q)
40
Grade D$22.43+7.4% Next Q
Q3 (-1Q)
42
Grade D$24.09+5% Next Q
Current
45
Grade D$25.30-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VRDN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VRDN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.68) and Max Pain ($26.57) forces dealer call-delta covering toward $36.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How VRDN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.02BGross Profit $529.1M (52%)Cost of Sales $488.4MOp Profit $0 (0%)OpEx (R&D/SG&A) $529.1MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $712.5M
FY24
Rev $837.3M
FY25
Rev $1.02B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$1.02B52%-35.7%-$342.6M-$276.9M-39.8%
FY 2024$837.3M52%-35.7%-$269.9M-$232.8M-34.1%
FY 2023$712.5M52%-35.7%-$237.7M-$184.2M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRDN)

  • ✓Walkthrough of VRDN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +79.94%⚡ TESTING RESISTANCE
2026-11-03O $24.80H $25.30L $24.67C $25.30VOL 1.71M
RES: $25.35SUP: $18.04SMA50: $21.68SMA200: $21.67
$26.16$22.69$19.23$15.77$12.31RES $25.35SUP $18.04$25.302026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VRDN Butterfly Map → + Track VRDN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VRDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRDN)

Health Care Rank #359 of 1015 ⚔️ VCRE vs VRDN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRDN vs. VCRE, MBX, NRIX, BHC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Viridian Therapeutics Inc. (VRDN) ranks #359 by composite RQD confidence (45/100, grade D) and #211 by equity capitalization ($2.79B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with VRDN at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VRDN ACTIVE
Viridian Therapeutics Inc.
D 45/100 — — -35.0% +2.55% $2.79B Benchmark Subject
VCRE
Vicore Pharma Holding AB
D 49/100 — — — -2.14% $2.76B /vcre-vs-vrdn →
MBX
MBX Biosciences Inc.
D- 40/100 — — -26.4% -2.63% $2.69B /mbx-vs-vrdn →
NRIX
Nurix Therapeutics Inc.
D 46/100 — — -35.0% -4.10% $2.93B /nrix-vs-vrdn →
BHC
Bausch Health Companies Inc.
C+ 68/100 21.2x — 7.6% -2.19% $3.07B /bhc-vs-vrdn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590750 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported GAAP revenue of $1.02B (+21.5% vs. FY2024 revenue of $837.3M , and +42.8% cumulative change since FY2023) , GAAP net income of -$342.6M, operating cash flow of -$276.4M, and free cash flow of -$276.9M (-18.9% YoY). On the balance sheet, VRDN closed FY2025 with $899.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.02B -$342.6M -$276.4M -$276.9M $899.4M —
FY2024 (FY) 2024-12-31 $837.3M -$269.9M -$232.3M -$232.8M $742.4M $20.6M
FY2023 (FY) 2023-12-31 $712.5M -$237.7M -$184.2M -$184.2M — —

3. VRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $25.30 (+2.55% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VRDN ranks #359 in composite RQD confidence.

How does VRDN compare to VCRE and MBX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRDN?

Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $1.02B in revenue (+21.5% YoY), -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRDN trading relative to its 50-day, 200-day, and 52-week technical levels?

VRDN last traded at $25.30 (+2.55% on volume of 3,391,297 shares), positioning the stock +16.70% above its 50-day simple moving average ($21.68) and +16.75% above its 200-day simple moving average ($21.67). Across its 52-week range of $13.18 to $34.29, VRDN sits at the 57.4% percentile with a 14-day RSI of 69.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.5% ($22.90 to $27.70).

Direct Sub-Reports: VRDN RQD Cockpit VRDN 12M Forecast VRDN Earnings & Move VRDN Dividends & DRIP VRDN Insiders & 13F VRDN Whale Options VRDN Profit Sankey VRDN News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

VRDN — Viridian Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Viridian Therapeutics Inc. (VRDN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $25.30 (+2.55% 1D, market capitalization $2.79B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -9.85%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Viridian Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..8B. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the source does not show a revenue-generating model in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported $1.02B in annual revenue (up from $837.3M in FY2024, +21.5% YoY) and -$342.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($712.5M revenue, -$237.7M net income) through FY2025, VRDN scaled operating cash flow to -$276.4M and free cash flow to -$276.9M, backed by $899.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -9.85% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $13.18 – $34.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VRDN carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can VRDN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.02B and free cash flow of -$276.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VRDN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VRDN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viridian Therapeutics Inc. (VRDN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VRDN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VRDN Bull vs. Bear Conversation Board — What's Your Call at $25.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRDN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VRDN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $30.10 (+22.0%)
📌 Pinned Debate

Whale/13F flow scores 14/20, the strongest RQD pillar, reflecting institutional accumulation and options positioning, alongside an RBC

Picked up a starter position in VRDN in my $100K Virtual Cash book at $24.67. Whale/13F flow scores 14/20, the strongest RQD pillar, reflecting institutional accumulation and options positioning, alongside an RBC Capital Buy rating with a $38 target.. Trading inside a $13.18–$34.29 52-week range with -9.85% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@BreakoutHunter Agree on the RQD 45/100 quality, though with 1.0 beta I'm scaling in with half-size at $24.67 and keeping dry powder in case we test $22.94.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $18.50 (-25.0%)
Spot @ $24.67

ROIC of -35%, FCF yield of -9.85%, and operating losses widening to -$363.4M in FY 2025 against $0.0M reported revenue leave the cash e

Careful chasing VRDN at $24.67. ROIC of -35%, FCF yield of -9.85%, and operating losses widening to -$363.4M in FY 2025 against $0.0M reported revenue leave the cash engine at 7/20.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $18.50 on multiple compression.

LIVE TAPE